ISRCTN13185152


PAnTher Cub: Procalcitonin-guided Antibiotic Therapy for febrile neutropenia in children and young people with cancer. A single-arm pilot study

Jessica E Morgan^{1,2} and Robert S Phillips^{1,2}

¹Department of Paediatric Haematology and Oncology, Leeds Children's Hospital, Leeds, UK

²Centre for Reviews and Dissemination, University of York, York, UK

• Participant Flow:



Baseline Characteristics:

Demographics: 13 unique patients; the median age was 6y 5m (range 8m to 18y) and 31% (4/13) were female.

Oncological grouping of patients

Tumour/Treatment group	Number of patients
rumour, recument group	italiae. o. patients

Stem cell transplant	2
Solid tumour	6
Brain tumour	1
Leukaemia	2
Lymphoma	2

• Outcome Measures:

Recruitment rate recorded as the number of eligible participants who consent to participate in the study over 6 months	28/32
Discontinuation adherence: proportion of episodes where antibiotics stopped according to PCT-guided recommendation over 6 months	4/8
2. Safety: number potentially infection-related admissions to critical care after discontinuation of antibiotics over 6 months	Zero
3. Recruitment strategy: proportion of potentially eligible patients who were approached to consent over 6 months	Unclear – assessing all eligible failed technically. Estimated 50% approached
4. Attrition: proportion of enrolled patients who then discontinued or declined intervention over 6 months	None
5. Data quality: proportion of missing data on primary outcome measures over 6 months	Between 100% - 40% depending on day
6. Impact on PCT on clinical decision making and reasons for adherence and non-adherence (qualitative data) 7. Patient, parent and clinician attitudes to study (qualitative data) including the outcomes	See full report for qual data
	number of eligible participants who consent to participate in the study over 6 months 1. Discontinuation adherence: proportion of episodes where antibiotics stopped according to PCT-guided recommendation over 6 months 2. Safety: number potentially infection-related admissions to critical care after discontinuation of antibiotics over 6 months 3. Recruitment strategy: proportion of potentially eligible patients who were approached to consent over 6 months 4. Attrition: proportion of enrolled patients who then discontinued or declined intervention over 6 months 5. Data quality: proportion of missing data on primary outcome measures over 6 months 6. Impact on PCT on clinical decision making and reasons for adherence and non-adherence (qualitative data) 7. Patient, parent and clinician attitudes to study (qualitative

• Adverse Events:

There were no adverse events associated with this trial.